Who owns Indaptus Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of INDP from SEC Form 13F filings across 9 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 9 institutions disclosed 384,994 shares of Indaptus Therapeutics, Inc. worth $1.2M — about 0.3% of shares outstanding; the largest disclosed holder is HRT FINANCIAL LP. Source: SEC Form 13F filings, parsed by EvidInvest.
9
13F holders
$1.2M
value, 2026 filers
0.3%
of shares outstanding (384,994 sh)
6
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of INDP's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | HRT FINANCIAL LPNEW | 206,077 | $618,000 | 0.0% | 0.2% | new |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 56,470 | $169,410 | 0.0% | 0% | +109.1% |
| 3 | JANE STREET GROUP, LLCNEW | 53,811 | $161,433 | 0.0% | 0% | new |
| 4 | VANGUARD CAPITAL MANAGEMENT LLCNEW | 33,652 | $100,956 | 0.0% | 0% | new |
| 5 | VANGUARD FIDUCIARY TRUST CONEW | 13,967 | $41,901 | 0.0% | 0% | new |
| 6 | MILLENNIUM MANAGEMENT LLCNEW | 11,586 | $34,758 | 0.0% | 0% | new |
| 7 | MORGAN STANLEY | 8,936 | $26,808 | 0.0% | 0% | +231.3% |
| 8 | UBS Group AGNEW | 478 | $1,434 | 0.0% | 0% | new |
| 9 | SBI Securities Co., Ltd. | 17 | $51 | 0.0% | 0% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.